NCT07218744View on ClinicalTrials.gov

Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

November 13, 2025

Primary Completion Date

December 8, 2025

Study Completion Date

December 8, 2025

Conditions

Healthy Participants

Interventions

DRUG

INCB123667

INCB123667 will be administered orally as a tablet dose, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY